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Currently, most cellular therapeutic effects for nervous diseases cannot
be proven in a multicenter, randomized, double-blind placebo-control
clinical trials, except for a few kinds of cells such as olfactory
ensheathing cells. These cells show significant improvements in
functional recovery and quality of life for patients with chronic
ischemic stroke. Also, olfactory neuron transplantation has promising
neurorestorative effects on patients with vascular dementia. Human
olfactory neuroepithelium can spontaneously and sustainably
regenerate or produce new olfactory neurons and glial cell types for
decades or a lifetime. The neurorestorative mechanisms of olfactory
ensheathing cells are well known; however, little is known about
the neurorestorative mechanisms of olfactory neurons. Therefore,
I hypothesize that the neurorestorative mechanisms of olfactory
neurons after transplantation: (1) can well migrate where they are
needed and become local functional neurons, as they need to compensate or replace; (2) must be regulated by some special molecular
factors to elongate their axons, modulate or direct synapses to
correctly recognize and connect the target cells, and integrate
functions. Based on olfactory neuroepithelium cells displaying
the special characterization, neurorestorative mechanisms, clinical
therapeutic achievements, and hypotheses of effective mechanisms,
they (olfactory ensheathing cells and olfactory neurons) may be the
most efficient instruments of neurorestoration.
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is published with open access at
http://jnr.tsinghuajournals.com
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Background

New neurons can be produced in the hippocampus
and the subventricular zone of the human adult
brain during trauma or diseases. Still, the number
and fate of new neuron production are limited

or insufficient to restore neurological dysfunction
or damaged structures. Autologous or allogeneic
cell transplantation is a selective therapeutic
method for nervous diseases. Unfortunately, the
neurorestorative effects from most cell therapies
(including neurons) in non-randomized clinical
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studies cannot be proven in multicenter, randomized, double-blind, placebo-control clinical trials
(Table 1) [1]. Currently, it is urgent and necessary
to find more effective cells for neurorestoration

to treat patients with neurological disorders. A
higher level of evidence-based medicine should
ably prove those cells.

Table 1 Results of cell therapies for neurological disorders.

Cell type

Disorders treated by small
sample, retrospective,
non-randomized doubleblind cell therapies

Results

Disorders treated by
multicenter, double
blinded, sham-controlled
RCT of cell therapies

Results

Neuron

Stroke, dementia

Effective [1–3]

Stroke

No effect [1, 2]

OEC

SCI, stroke, etc.

Effective [1, 2]

Stroke

Effective [4]

Mononuclear cell

SCI, CP, stroke, etc.

Effective [1, 2]

Stroke, CP

Effective for CP combined with
erythropoietin;
No effect for stroke and CP [5]

MSC

SCI, stroke, MS

Effective [1, 2]

SCI, stroke, MS

Effective for MS [6]
No effect for SCI, not or partially
improve motor functions for
stroke without improving quality
of life [2, 7, 8]

Schwann cell

SCI

Effective [1]

None

–

Fetal brain and
spinal cord cell

SCI

Effective [1]

None

–

Hematopoietic
stem cell

MS, SCI, ALS, etc.

Effective [1]

MS

No effect [1]

Cells differentiated
from ESC

SCI, MD

Effective for MD;
SCI
No effect for SCI [1]

No effect [1]

Cells differentiated
from induced pluripotent stem cells

PD, MD

Effective for PD;
None
No effect for MD [1]

–

Cells differentiated
from MSC

Stroke, CP, ALS, TBI, etc.

Effective [1]

Stroke, TBI, ALS

No effect for stroke and ALS
[2, 9], or partially improve motor
functions for TBI without
improving quality of life [10]

Cell differentiated
from neural stem
cells

Stroke, CP, MD, TBI, etc.

Effective [1]

None

–

RCT, randomized controlled trial; OEC, olfactory ensheathing cell; MSC, mesenchymal stromal cell; ESC, embryonic stem cell; SCI,
spinal cord injury; CP, cerebral palsy; MS, multiple sclerosis; MD, macular degeneration; PD, Parkinson’s disease; ALS, amyotrophic
lateral sclerosis; TBI, traumatic brain injury.
Note: 1. Olfactory ensheathing cells are the only cells which improve the quality of life for patient with stroke in multicenter,
double blinded, sham-controlled RCT of cell therapies. Neurons, mononuclear cells, MSCs, and cells differentiated from MSCs
do not improve quality of life for stroke patients in this level trial. 2. Combined treatment using mononuclear cells with
erythropoietin improves the neurological functions for CP in RCT, but using mononuclear cells only show no effect. This implies
that combinations may be important for cells to restore damaged nerves. 3. Mesenchymal stromal cells can suppress the activity
of progressive MS and reduce its relapse rate in RCT. The mechanisms of MSCs as well as their paracrine or exosomes are to
mediate anti-inflammatory and tissue repair functionalities [11], which are specially fit for treating immunological diseases,
such as MS.
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2 The basic characterization of the olfactory
neuroepithelium
The presence of active neurogenesis in the adult
human nervous system, except for the olfactory
neuroepithelium, is still controversial. The human
olfactory neuroepithelium has a strong ability
to spontaneously and sustainably regenerate or
produce new neurons for decades or a lifetime
[12, 13]. Immature and mature olfactory neurons
(ONs) in adult humans are dispersed throughout
the olfactory neuroepithelium [14]. This means
that olfactory stem cells from olfactory mucosa
or neuroepithelium can differentiate into progenitors, which proliferate or produce neurons
and glial cells, including olfactory ensheathing
cells (OECs) [15].

3 Achievements in the clinical application
of OECs and ONs for nervous diseases
and damage
3.1

Olfactory ensheathing cells

Huang et al. were the first to report that patients
with chronic complete spinal cord injury (SCI)
could improve their neurological functions and
quality of life following OEC transplantation [16].
Later, there were more reports about OEC
transplantation for patients with SCI [17–33],
and most of them showed improvements in
neurological functions and quality of life.
However, only a few studies have reported no
improvements or even a little worse [34, 35], which
might result from translating procedure damage
[36]. Olfactory mucosa autograft transplantation
also showed neurological improvements for
patients with SCI [37, 38], but the results could
not be repeated [39], especially in the shamcontrolled study with no remarkable differences in
assessing neurological function between treated
and control groups [40]. A more severe issue was
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that a mass formation following olfactory mucosal
tissue transplantation pressed or impaired
surrounding nerve and caused neurological
symptoms [41, 42].
OEC or combined with other kinds of cell
transplantation also showed benefits for patients
with nervous diseases or damage [43], such as
stroke [44–46], cerebral palsy (CP) [47, 48], severe
head-injury or craniocerebral injury [49, 50],
comatose states [51], amyotrophic lateral sclerosis
(ALS) [52–54], multiple system atrophy (MSA)
[55], postpoliomyelitis syndrome [56], SCI [57–60],
and sciatic nerve injury [61].
A recent report of a multicenter, randomized,
double-blind, placebo-controlled cell therapy trial
for patients with chronic ischemic stroke showed
significant differences in functional recovery and
quality of life among the OEC-treated, Schwann
cell-treated, and placebo groups [4].
3.2

Olfactory neurons

In one pilot study, ONs showed promising
neurorestorative effects for patients with vascular
dementia by assessment of Mini-Mental Status
Examination, Montreal Cognitive Assessment,
and Clinical Dementia Rating [3]. Therefore, a
phase II clinical trial of ONs is needed to verify
those effects.

4 Exploring neurorestorative mechanisms
of OECs
Olfactory ensheathing cells are special glial cells
in the olfactory bulb and mucosa; they display
Schwann cell and astrocyte properties. In immunochemical staining, they display astrocyte (GFAP),
Schwann cell (P75), and oligodendrocyte markers
(O4). They guide olfactory axons from peripheral
olfactory neuroepithelium into the olfactory bulb
of the central nervous system [62]. Also, they can
unrestrainedly go through the barrier between the
peripheral nervous system and central nervous
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system when transplanted into the transected
dorsal root area [63]. Neurorestorative mechanisms
of OECs include neuroprotection [64–68], axonal
regeneration [69–74], remyelination [70, 75, 76],
neural network or circuitry reconstruction [73],
neuroplasticity [77, 78], neuromodulation [67, 79],
anti-inflammatory response or immunomodulation [66, 80–82], promoting neurogenesis [77, 83],
and stimulating angiogenesis [68, 74].

5

Hypotheses about
mechanisms of ONs

neurorestorative

After new ONs are produced, their axons and
synapses must elongate to connect target cells
or original neurons of the olfactory nerve system
and integrate functions with strong support
from OECs. Murrell et al. hypothesized that the
presence of a sufficiently primitive “stem cell” of
the olfactory mucosa would exhibit potency in
response to the environment where the cells are
placed [15]. Additionally, a study showed that in
vitro ONs cultured in a special medium possess
characteristics of photoreceptor cells [84]. More
studies showed that human olfactory systemderived stem cells differentiating and proliferating
into dopaminergic neuron-like cells in a special
culture medium [85–87]. In experimental studies,
transplanting olfactory mucosa stem cells in
Parkinson’s animal models found cells with
dopaminergic neuron markers in different brain
areas [88, 89]. Also, transplanting olfactory mucosa
stem cells benefits SCI and peroneal nerve injury
[90, 91]. Based on basic and pre-clinical studies,
and considering the pilot study results of ONs [3],
my hypotheses of neurorestorative mechanisms
of ONs from olfactory neuroepithelium are that
after transplantation, they (1) can well migrate
where they are needed and become local
functional neurons as they need to compensate
or replace; (2) must be regulated by some special
molecular factors to elongate their axons, modulate

or direct the synapses to correctly recognize,
connect the target cells, and integrate functions.
Therefore, knowing those issues or proving those
hypotheses is important for transplanting ONs
to better restore neurological dysfunction and
damaged structures.

6

Summary and prospect

Olfactory ensheathing cells have firmly shown
neurorestorative effects for chronic ischemic stroke
in higher levels of evidence-based medicine,
and their neurorestorative mechanisms are well
known. Also, ONs have shown promising effects
in vascular dementia with little knowledge of
their neurorestorative mechanism. Therefore, it
is urgent and necessary to deeply explore the
neurorestorative mechanisms of ONs and prove
the above mentioned hypotheses in basic and preclinical studies. More clinical trials of OECs, ONs,
or a combination with higher levels of evidencebased medicine should also be conducted. Based
on olfactory neuroepithelium cells displaying
the special characteristics, neurorestorative
mechanisms, clinical therapeutic achievements,
and hypotheses of ON effective mechanisms, they
(OECs and neurons) may be the most efficient
instruments as cell therapy for neurorestoration.
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